Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Jubelirer

Pediatrics Murray, UT Medical Doctor

NPI 1487634960 CMS profile 775645

6065 S Fashion Blvd, Suite 255, Murray, UT 84107

Open in the dashboard

General payments

$1,735

97 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Jubelirer of Murray, UT is reported in the CMS Open Payments database as having received $1,735 across 97 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $499 14
2024 General $454 32
2023 General $318 16
2022 General $211 16
2021 General $55 4
2020 General $12 1
2019 General $186 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Jubelirer
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to David Jubelirer were reported at $499. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year David Jubelirer Pediatrics median Middle half National median
2019 $186 $86 $31–$183 $163
2020 $12 $49 $22–$110 $114
2021 $55 $68 $27–$158 $132
2022 $211 $77 $30–$173 $149
2023 $318 $88 $33–$190 $160
2024 $454 $94 $34–$206 $164
2025 $499 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Tris Pharma Inc $951 39 payments
  2. Supernus Pharmaceuticals, Inc. $253 18 payments
  3. Corium, Inc. $167 17 payments
  4. Ironshore Pharmaceuticals Inc. $108 6 payments
  5. Shire North American Group Inc $79 6 payments
  6. Collegium Pharmaceutical, Inc. $72 4 payments
  7. Boston Scientific Corporation $32 2 payments
  8. Arbor Pharmaceuticals, Inc. $30 2 payments
  9. Vertical Pharmaceuticals, LLC $16 1 payment
  10. Noven Therapeutics, LLC $14 1 payment
  11. Other $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,728 96 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. Dyanavel XR Adhd $746 35 payments
  2. QELBREE Psychology $216 17 payments
  3. Azstarys $167 17 payments
  4. VYVANSE $91 7 payments
  5. Dyanavel XR Adhd $80 3 payments
  6. JORNAY PM Central Nervous System Stimulant $72 3 payments
  7. Jornay PM Adhd $72 4 payments
  8. Quillichew ER $53 1 payment
  9. Quillivant $53 1 payment
  10. Qelbree Viloxazine Hydrochloride $38 1 payment
  11. Other $129 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

97

Median for Pediatric Medicine: 38

Drug cost

$3,254

Median for Pediatric Medicine: $2,769

Branded share of claims

87.6%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 53 $1,679
Dexmethylphenidate Hcl Er Dexmethylphenidate Hcl Brand 15 $791
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 17 $777
Clonazepam Generic 12 $7

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Dyanavel XR
  • Tris Pharma Inc $261
$261 — —
Azstarys
  • Corium, Inc. $107
$107 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $72
$72 — —
Xelstrym
  • Noven Therapeutics, LLC $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

97 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record